WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #chronicpain–NeuroMetrix, Inc. (NASDAQ:NURO, NUROW) today announced that Shai N.
Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled
to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel
Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on
the Company’s business activities including the Quell® Wearable
Pain Relief Technology™.
The NeuroMetrix presentation is scheduled for Tuesday, December 6, 2016,
at 8:00 a.m. Pacific Time (11:00 a.m. Eastern). A live audio webcast
will be available on the investor relations section of the corporate
website – http://www.NeuroMetrix.com/.
This webcast will be archived after the live event.
Quell utilizes NeuroMetrix’s patented neurostimulation technology to
provide widespread relief from chronic pain. The advanced wearable
device is lightweight and can be worn during the day while active, and
at night while sleeping. It has been cleared by the FDA for treatment of
chronic pain without a prescription. In a recent study, 81% of Quell
users reported an improvement in their chronic pain. Quell was recently
named “Winner” in the Wearable Tech category at the SXSW Interactive
Innovation Awards. It is available for purchase at QuellRelief.com,
selected retailers and healthcare professionals.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into an event
platform hosting several influential conferences annually (Invitational,
Summit, and Main Event). In 2015, LDM launched the first pure microcap
index (the LDMi) to exclusively provide intraday information on the
entire sector. For more information, visit www.ldmicro.com.
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company’s lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs, including a therapeutic device for restless
leg syndrome. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer